Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Research
  • DPHARM: How to address the clinical trial enrollment crisis?

DPHARM: How to address the clinical trial enrollment crisis?

September 17, 2026Posted inResearch

Clinical trials are facing an enrollment crisis. Around 80% of trials don’t meet their enrollment timelines, and fewer than 5% of eligible adult cancer patients participate in trials.

Post navigation

Previous Post
After one failed acquisition attempt, Lisata finds lifeline in Marea merger
Next Post
Goa Therapeutics launches with ‘immeasurably huge’ vision of creating Narcan for alcohol

Recent Posts

  • Sartorius and NIBRT Partner on Intensified and Continuous Bioprocessing Training Center
  • Mithrl Raises $20M to Expand Deployment of Its Biomedical World Model Across Biopharma
  • Goa Therapeutics launches with ‘immeasurably huge’ vision of creating Narcan for alcohol
  • DPHARM: How to address the clinical trial enrollment crisis?
  • After one failed acquisition attempt, Lisata finds lifeline in Marea merger

Archives

  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • March 2024
  • January 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top